FDA approves the first immunotherapy regimen for platinum-resistant ovarian cancer with a proven survival benefit

Evidence stage: Later-Stage HumanRegulatory status: FDA-approved for the exact stated cancer/useGuideline status: Not addressed

The FDA approved pembrolizumab (Keytruda) in combination with paclitaxel, with or without bevacizumab, for adults with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal carcinoma who have received one to two prior lines of systemic therapy and whose tumors express PD-L1 (CPS >=1, per a companion diagnostic test) — the first immune checkpoint inhibitor regimen to demonstrate a statistically significant overall-survival benefit in a phase 3 ovarian cancer trial. The approval was based on the randomized, double-blind, phase 3 ENGOT-ov65/KEYNOTE-B96 trial (ClinicalTrials.gov NCT05116189; primary publication in The Lancet, DOI 10.1016/S0140-6736(26)00602-1, PMID 41974150), conducted at 187 gynaecologic oncology centres in 25 countries and enrolling 643 patients. Among PD-L1-positive participants, progression-free survival improved from 7.2 to 8.3 months (hazard ratio 0.72, P=.0014) and overall survival improved from 14.0 to 18.2 months (hazard ratio 0.76, P=.0053) with pembrolizumab added — real, statistically significant benefits on both endpoints.

What This Means

In the randomized, phase 3 ENGOT-ov65/KEYNOTE-B96 trial, adding pembrolizumab to paclitaxel chemotherapy significantly improved BOTH progression-free survival (8.3 vs 7.2 months) AND overall survival (18.2 vs 14.0 months) in patients with PD-L1-positive, platinum-resistant ovarian cancer -- the first immune checkpoint inhibitor regimen to show a statistically significant survival benefit in a phase 3 ovarian cancer trial.

What This Doesn't Mean

This approval is specifically for PD-L1-POSITIVE (CPS >=1) disease, confirmed by a companion diagnostic test -- it does not apply to PD-L1-negative platinum-resistant ovarian cancer, for which this specific benefit was not demonstrated. Platinum-resistant disease is a specific clinical category (recurrence within 6 months of platinum-based chemotherapy) -- this record makes no claim about platinum-sensitive disease.

Why It Matters

Ovarian cancer has historically shown disappointing results with immune checkpoint inhibitors compared with other cancer types -- a confirmed, statistically significant survival benefit in a well-powered, randomized phase 3 trial is a genuine, meaningful advance for a population with historically very limited options, and adds real depth to this site's ovarian cancer coverage.

Promise & Proof

Proof — strength of the evidence 5 / 5
  • Base score from evidence stage: Later-Stage Human.
  • FDA-approved for the exact stated cancer/use.
Promise — potential significance if later evidence holds up 4 / 5
  • Baseline — a validly-evidenced story starts here; every further point below is an explicit, checkable reason.
  • The record includes substantive editorial reasoning about why this discovery matters.
  • A distinct follow-on/confirmatory study or trial is already cited as a secondary source — the field is already building on this finding.
  • Targets a cancer type with historically limited effective treatment options.

These two ratings are automatically computed from this story's own structured evidence fields and are shown separately on purpose — they are never combined into one score. They describe this record, not a medical recommendation: they do not establish medical certainty, do not substitute for reading the cited sources, and are recalculated whenever the underlying evidence changes.

Population / Applicability

Studied in: Adults with platinum-resistant, PD-L1-positive (CPS >=1) epithelial ovarian, fallopian tube, or primary peritoneal carcinoma who had received one to two prior lines of systemic therapy, randomized to pembrolizumab plus paclitaxel (+/- bevacizumab) or placebo plus paclitaxel (+/- bevacizumab), in the randomized, double-blind, phase 3 ENGOT-ov65/KEYNOTE-B96 trial conducted at 187 sites in 25 countries. (Adults)

Requires PD-L1 testing (CPS >=1) before use via a companion diagnostic. This record has not independently reviewed the full safety/tolerability profile, which should be added before publication.

Full evidence details
Study design
Randomized controlled trial
Sample size
643

Funding & Conflicts

Sponsor/developer: Merck & Co., Inc. -- not independently confirmed against a primary corporate-disclosure document.

Regulatory status by jurisdiction

United States (FDA)

Status
FDA-approved for the exact stated cancer/use
Indication
Adults with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal carcinoma whose tumors express PD-L1 (CPS >=1), who have received one to two prior lines of systemic therapy.
Biomarker requirement
PD-L1 CPS >=1 (PD-L1 IHC 22C3 pharmDx)
Decision date
2026-02-10
Source
Regulator record (opens in a new tab)

Guideline positions

Guideline

Position
Not addressed
Last verified
2026-08-13

Primary evidence supporting this story

Additional context

Why Should I Trust This?

  • 1 source at Tier 2 — Peer-reviewed primary research, trial registries, regulatory documents, official conference abstracts
  • Last reviewed: 2026-08-13

This panel summarizes real, checkable facts about this record's own sources and review status — it is not a trust score, and reading it is not a substitute for reading the cited sources yourself.

Discovery Timeline

Every recorded change to this record's content or publication status, in order.

  1. Status change — Status changed from "Legacy / Unverified" to "In editorial review".
  2. Status change — Status changed from "In editorial review" to "Verified".

Last reviewed

Related discoveries

FDA approves the first immunotherapy regimen for platinum-resistant ovarian cancer with a proven survival benefit

https://cancerdiscoveries.com/discoveries/fda-approves-the-first-immunotherapy-regimen-for-platinum-resistant-ovarian-cancer-with-a-proven-survival-benefit/

Evidence stage: Later-Stage Human

What This Means

In the randomized, phase 3 ENGOT-ov65/KEYNOTE-B96 trial, adding pembrolizumab to paclitaxel chemotherapy significantly improved BOTH progression-free survival (8.3 vs 7.2 months) AND overall survival (18.2 vs 14.0 months) in patients with PD-L1-positive, platinum-resistant ovarian cancer -- the first immune checkpoint inhibitor regimen to show a statistically significant survival benefit in a phase 3 ovarian cancer trial.

What This Doesn't Mean

This approval is specifically for PD-L1-POSITIVE (CPS >=1) disease, confirmed by a companion diagnostic test -- it does not apply to PD-L1-negative platinum-resistant ovarian cancer, for which this specific benefit was not demonstrated. Platinum-resistant disease is a specific clinical category (recurrence within 6 months of platinum-based chemotherapy) -- this record makes no claim about platinum-sensitive disease.

Why It Matters

Ovarian cancer has historically shown disappointing results with immune checkpoint inhibitors compared with other cancer types -- a confirmed, statistically significant survival benefit in a well-powered, randomized phase 3 trial is a genuine, meaningful advance for a population with historically very limited options, and adds real depth to this site's ovarian cancer coverage.

Primary sources

  • Pembrolizumab plus weekly paclitaxel in platinum-resistant recurrent ovarian cancer (ENGOT-ov65/KEYNOTE-B96): a multicentre, randomised, double-blind, phase 3 study (The Lancet) — https://doi.org/10.1016/S0140-6736(26)00602-1 (DOI 10.1016/S0140-6736(26)00602-1, PMID 41974150)

Date verified: 2026-08-13

Correction status: No correction or retraction